Chodobski A, Szmydynger-Chodobska J, Johanson C E
Program in Neurosurgery, Department of Clinical Neurosciences, Brown University/Rhode Island Hospital, Aldrich Bldg., Rm. 403, 593 Eddy Street, Providence, RI 02903,
Brain Res. 1999 Jan 23;816(2):518-26. doi: 10.1016/s0006-8993(98)01220-7.
Blood flow to the rat choroid plexus has minimal variability when plasma angiotensin II (AII) concentration is changed within a broad range of levels. We tested the hypothesis that a complex interplay of the vasoconstrictor and vasodilator AII actions in choroidal tissue results in small net changes in choroidal blood flow. Blood flow was measured with 123I- or 125I-N-isopropyl-p-iodoamphetamine. AII was infused intravenously (i.v.) at 30 (moderate dose) and 300 ng kg-1 min-1 (high dose), which respectively decreased (15%) and did not change choroidal blood flow. To determine whether AII regulates choroidal blood flow by interacting with the sympathetic nervous system, rats were given phentolamine (1 mg kg-1, i.v.). This alpha-adrenoceptor antagonist by itself did not alter blood flow; however, it attenuated the blood flow-lowering effect of moderate AII dose. Phentolamine also unmasked the vasodilator AII actions at high peptide concentration. beta-Adrenoceptor blockade, with propranolol (1 mg kg-1, i.v.), reduced blood flow (18-20%) and increased vascular resistance (23-26%). During beta-adrenoceptor blockade, a further decrease in blood flow (15-21%) and increase in vascular resistance (23%) was noted when high AII dose was administered. The direct vasoconstrictor effect of AII at moderate dose on choroidal vasculature was examined in rats subjected to chronic bilateral superior cervical ganglionectomy. In these animals, AII decreased blood flow (24%) and increased vascular resistance (24%). To find out whether the hemodynamic AII actions in choroidal tissue are mediated by nitric oxide (NO), Nomega-nitro-l-arginine methyl ester (l-NAME) was used. l-NAME (0.1 mg kg-1, i.v.) by itself did not alter blood flow; however, in l-NAME-treated rats high AII dose lowered blood flow (25-32%) and increased vascular resistance (30-43%). We conclude that the vasoconstrictor AII actions involve a direct peptide effect on the choroidal vascular bed, and the AII-mediated potentiation of sympathetic activity, which results in the activation of alpha-adrenoceptors. The AII-mediated stimulation of sympathetic nerves also results in the beta-adrenoceptor-dependent relaxation of choroidal blood vessels. In addition, choroidal vasodilatory actions of AII are NO-mediated.
当血浆血管紧张素II(AII)浓度在很宽的水平范围内变化时,大鼠脉络丛的血流变化极小。我们检验了这样一个假说,即脉络丛组织中血管收缩剂和血管舒张剂AII作用之间的复杂相互作用导致脉络丛血流的净变化很小。用123I-或125I-N-异丙基-p-碘安非他明测量血流。以30(中等剂量)和300 ng·kg-1·min-1(高剂量)静脉内(i.v.)输注AII,这分别使脉络丛血流减少(15%)和无变化。为了确定AII是否通过与交感神经系统相互作用来调节脉络丛血流,给大鼠注射酚妥拉明(1 mg·kg-1,i.v.)。这种α-肾上腺素能受体拮抗剂本身不改变血流;然而,它减弱了中等剂量AII降低血流的作用。酚妥拉明还在高肽浓度时揭示了AII的血管舒张作用。用普萘洛尔(1 mg·kg-1,i.v.)阻断β-肾上腺素能受体,使血流减少(18 - 20%)并增加血管阻力(23 - 26%)。在β-肾上腺素能受体阻断期间,当给予高剂量AII时,观察到血流进一步减少(15 - 21%)和血管阻力增加(23%)。在慢性双侧颈上神经节切除的大鼠中研究了中等剂量AII对脉络丛血管系统的直接血管收缩作用。在这些动物中,AII使血流减少(24%)并增加血管阻力(24%)。为了弄清楚脉络丛组织中AII的血流动力学作用是否由一氧化氮(NO)介导,使用了Nω-硝基-L-精氨酸甲酯(L-NAME)。L-NAME(0.1 mg·kg-1,i.v.)本身不改变血流;然而,在L-NAME处理的大鼠中,高剂量AII使血流减少(25 - 32%)并增加血管阻力(30 - 43%)。我们得出结论,血管收缩剂AII的作用涉及对脉络丛血管床的直接肽作用,以及AII介导的交感神经活动增强,这导致α-肾上腺素能受体激活。AII介导的交感神经刺激还导致脉络丛血管的β-肾上腺素能受体依赖性舒张。此外,AII的脉络丛血管舒张作用由NO介导。